Hear+Now: An AI-Powered Audio Digest – What Gaps Do Patients See With Their HCPs?

In this audio digest, we’re unpacking data and patient insights from our 2025 Myasthenia Gravis In America survey. We dive into the "diagnostic odyssey," the lingering impact of clinical dismissal, and the surprising percentage of patients who feel stigmatized by the medical community itself.

Join us as we go behind the curtain to explore the emotional and systemic hurdles your patients navigate long before they sit on your exam table – and how you can transform your next appointment from a standard checkup into a truly collaborative partnership.

Before listening in, take our quiz to see if you can guess the insights gleaned from our Myasthenia Gravis 2025 In America Survey.

This audio digest was generated with the assistance of an AI tool and reviewed by a member of our Editorial Team and Health Union Medical Review Board. This information is provided for general knowledge and is not a substitute for professional medical advice.

Transcript:

Speaker 1: Today, we're unpacking patient data and responses from our Myasthenia Gravis 2025 In America survey.

Speaker 2: Yeah, and it's a really comprehensive look featuring feedback from both patients and caregivers.

Speaker 1: Right. And our mission today is to really uncover those hidden gaps, the friction points that your myasthenia gravis patients are experiencing outside your clinic walls.

Speaker 2: Because, I mean, you might only see a patient for a 15 or 30-minute window.

Speaker 1: Yeah, exactly.

Speaker 2: This data captures the other 99% of their lives. For your daily practice, understanding these blind spots is just crucial. It gives you this exclusive look behind the curtain at the systemic and emotional hurdles they navigate long before they even sit on your exam table.

Speaker 1: Let's start with the very beginning of their journey, which is the diagnostic odyssey. Just getting to a definitive diagnosis is a massive hurdle for this population.

Speaker 2: The survey lays out a pretty stark timeline. On one end, you have 25% of patients who get a diagnosis in under a month.

Speaker 1: Which is great.

Speaker 2: It is. But on the other end nearly one in ten suffer for more than five years before getting formal confirmation.

Speaker 1: Over five years. That is just incredible.

Speaker 2: Yeah. Essentially, a full third of these patients are experiencing this trifecta of clinical frustration. They're seeing multiple providers, getting misdiagnosed, and having their symptoms completely dismissed early on.

Speaker 1: And 32% reported that their symptoms were initially dismissed by providers.

Speaker 2: Which sets such a difficult tone for future medical interactions. There's an open-ended survey response that really captures this.

Speaker 1: The patient wrote. A patient can tell you what their body is experiencing. Don't just go by textbooks. I feel my doctor isn't very familiar with myasthenia.

Speaker 2: That's a powerful reminder. It really highlights that recurring tension between clinical textbook knowledge and the messy lived reality of the disease. And this tension persists even after they're established with a care team.

Speaker 1: Right.

Speaker 2: While 53% of patients are extremely satisfied with their primary MG provider, there are glaring blind spots.

Speaker 1: Like what?

Speaker 2: Well, 12% of patients feel their doctor doesn't know enough about the condition and 14% say it's genuinely hard to fully express their treatment needs during an appointment.

Speaker 1: Are they holding back because of those past dismissals? Or is there something else driving that hesitation to speak up?

Speaker 2: The data points heavily toward a lingering sense of stigma: 45% of patients report feeling stigmatized or judged for having MG.

Speaker 1: Wow, by the medical community itself?

Speaker 2: Yes. Fifteen percent report feeling stigmatized by urgent care or ER doctors and 8% experience it directly with their primary care providers.

Speaker 1: Listen to this raw feedback from another patient. 'I often feel very broken, and I hate my body that betrays me.'

Speaker 2: Mmmm.

Speaker 1: They need you to be an ally, not just a prescriber. They're carrying this heavy emotional weight into every appointment.

Speaker 2: And that psychological weight translates directly into how they approach their care plan. We are looking at a highly empowered yet very anxious patient population. 65% of these patients actively seek out information about the latest treatments on their own.

Speaker 1: Is that independent research driven by general curiosity? Or is it rooted in a lack of faith in their current treatment?

Speaker 2: It’s largely driven by anxiety and unmet clinical needs. Over a third are highly concerned about the long-term side effects of their treatments, and 29% feel that the currently available therapies simply do not fully manage their symptoms.

Speaker 1: Makes sense.

Speaker 2: So they're searching for alternatives because the status quo leaves them feeling vulnerable. And on top of that, they're juggling massive logistical stresses. The survey shows 61% worry about employment stability, and half of them are stressing over something as fundamental as having reliable transportation just to make it to their appointments.

Speaker 1: Understanding that holistic context is vital. Medical decisions don't happen in a vacuum. Knowing this helps you see why a patient might resist a new therapy if it requires more frequent clinic visits.

Speaker 2: Exactly. Or why they might seem distracted when you're discussing lab results. Right.

Speaker 1: Right, the logistics of managing the disease are often just as taxing as the symptoms themselves.

Speaker 2: Recognizing the systemic frictions they've battled just to be sitting in front of you can fundamentally change the dynamic of your clinic visits.

Speaker 1: So to summarize, treating MG effectively goes way beyond textbooks. It requires validating the patient's lived experience and bridging that communication gap.

Speaker 2: We will leave you with this final provocative thought to mull over: Since 65% of your MG patients are actively researching new treatments on their own, how can you transform your brief clinic visits from standard checkups into collaborative spaces where their independent research is genuinely welcomed rather than dismissed?